Related Experiment Video
Updated: Jan 18, 2026

A Mouse Ear Model for Allergic Contact Dermatitis Evaluation
Published on: March 24, 2023
Pediatric Atopic Dermatitis Exhibits Distinctive Patterns in JAK/STAT Pathway Activation and CD6-ALCAM Signaling
Soyoung Jeong1, Sanghee Shin2, Hyun Seung Choi1
1Department of Biomedical Sciences, Seoul National University Graduate School, Seoul 03080, Korea.
Insights
Pediatric atopic dermatitis (AD) has unique immune signatures, differing from adult AD. Findings suggest age-specific treatments are crucial for effective management of this skin condition.
Area of Science:
- Immunology
- Dermatology
- Genetics
Background:
- Pediatric atopic dermatitis (AD) presents unique clinical features compared to adult AD.
- These differences suggest distinct inflammatory profiles influencing disease course and treatment efficacy.
Purpose of the Study:
- To identify specific immune signatures in pediatric AD.
- To compare the immune phenotypes between pediatric and adult AD patients.
Main Methods:
- Single-cell RNA sequencing was used to analyze transcriptomic profiles of PBMCs.
- Immune phenotypes were compared between pediatric AD, adult AD, and age/sex-matched healthy controls (HCs).
Main Results:
- Th2 gene expression was elevated in both pediatric and adult AD.
- Pediatric AD showed downregulated Th1, Th17, and Th22 gene expression, unlike adult AD.
- The JAK/STAT signaling pathway was upregulated in adult AD but not pediatric AD.
- The CD6-activated leukocyte cell adhesion molecule (ALCAM) pathway was upregulated in pediatric AD.
Conclusions:
- Pediatric AD exhibits distinct immune signatures, including the absence of JAK/STAT pathway upregulation and unique CD6-ALCAM pathway activation.
- These age-specific differences underscore the need for tailored treatment strategies in atopic dermatitis management.
Abstract:
Pediatric atopic dermatitis (AD) shows distinct clinical characteristics compared to adult AD, suggesting unique inflammatory profiles that may influence disease prognosis and treatment response. We aimed to identify unique immune signatures of pediatric AD and investigate the differences between pediatric and adult AD patients. Nine pediatric (6-16 years) and 12 adult (20-60 years) were enrolled. PBMCs were collected from AD patients and age- and sex-matched healthy controls (HCs). Transcriptomic profiles were analyzed using single-cell RNA sequencing, and the immune phenotypes of adult and pediatric AD were compared. Th2 gene expression was elevated in both adult and pediatric AD, while Th1, Th17, and Th22 gene expression was downregulated in pediatric AD but not in adults. Genes involved in JAK/STAT signaling pathway, which were upregulated in adult AD, were not significantly increased in pediatric AD. The CD6-activated leukocyte cell adhesion molecule (ALCAM) pathway was upregulated in pediatric AD compared to pediatric HCs, but not in adult AD. Pediatric AD reveals distinct immune signatures, including a lack of JAK/STAT pathway upregulation observed in adult AD and a unique activation of the CD6-ALCAM pathway. These findings highlight the importance of age-specific treatment strategies in AD patients.
Related Concept Videos
The JAK-STAT Signaling Pathway
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
cAMP-dependent Protein Kinase Pathways

